Records containing: Neuroendocrine Neoplasm
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2021-11-24Chidamide and Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Study
-
CLINICAL_TRIALS study record update · 2021-09-24Single-cell Sequencing and Establishment of Cell Lines, Organoids, and Transplanted Tumor Models in Neuroendocrine Neoplasm
-
CLINICAL_TRIALS study record update · 2021-06-18Research on Neuroendocrine Neoplasm in a Single Center Based on Multi-omics Integrated Analysis
-
CLINICAL_TRIALS study record update · 2021-02-15An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC
-
CLINICAL_TRIALS study record update · 2021-01-22Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2020-07-22A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of ZSP1602 in Participants With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2018-04-30A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
-
CLINICAL_TRIALS study record update · 2017-09-28A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2016-04-28Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients